Quarterly ResultAug 6, 2026, 07:38 AM
Lexicon Pharmaceuticals Q2 Net Loss $31.8M; Clinical Updates
AI Summary
Lexicon Pharmaceuticals reported a net loss of $31.8 million for Q2 2026, compared to a net income of $3.3 million in Q2 2025. Total revenues significantly decreased to $0.7 million from $28.9 million year-over-year, primarily due to lower licensing revenue. The company also provided positive clinical updates, including the completion of enrollment for the Phase 3 SONATA-HCM study with top-line data expected in Q1 2027, and nearing completion of NDA resubmission activities for ZYNQUISTA® in type 1 diabetes. Additionally, Novo Nordisk's Phase 1 clinical development of LX9851 is ongoing, and the company secured a new $100 million loan facility.
Key Highlights
- Q2 2026 net loss $31.8 million ($0.07/share) vs. $3.3 million net income in Q2 2025.
- Total revenues for Q2 2026 were $0.7 million, down from $28.9 million in Q2 2025.
- Enrollment completed for Phase 3 SONATA-HCM study; top-line data expected Q1 2027.
- NDA resubmission for ZYNQUISTA® in T1D nearing completion, anticipated Q4 2026.
- Novo Nordisk initiated Phase 1 study for LX9851 in obesity, expected completion Q1 2027.
- Cash and investments $190.6 million as of June 30, 2026, up from $125.2 million.
- Secured $100 million loan facility with Hercules Capital; $55 million funded.
Price Impact
More from LXRX